SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP

SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP

Background: Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Nowadays, DOACs represent the gold standard for long-term anticoagulation, with low-intensity DOACs administration becoming increasingly used worldwide in such...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini
Format: Article
Language:English
Published: PAGEPress Publications 2024-02-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
dose-reduced
Deep vein thrombosis
Direct oral anticoagulants (DOACs)
Venous thromboembolism secondary prophylaxis
VTE recurrence
Bleeding adverse events
Online Access:https://www.mjhid.org/mjhid/article/view/5567
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items